Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
23
pubmed:dateCreated
2010-12-8
pubmed:abstractText
Current cancer management aims to integrate molecular signatures into the design of personalized therapies. Recent advances in "omics" done on tumor specimens have led to the identification of factors that either recognize cancers of dismal prognosis or pinpoint "druggable" signaling pathways, which can be interrupted by targeted therapies. However, accumulating evidence underscores the biological and clinical significance of immune predictors in several compartments (blood, serum, tumor) in a variety of malignancies. An additional aspect that has been overlooked is the bidirectional, tumor-host interaction during therapeutic intervention, suggesting that dynamic molecular, biochemical, and metabolic signatures should be developed in the future. We review immune parameters of prognostic or predictive value during cancer therapy, and highlight existing "descriptive-prognostic" and "functional-therapeutic" molecular signatures, with the hindsight of designing appropriate compensatory therapies.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
1538-7445
pubmed:author
pubmed:issnType
Electronic
pubmed:day
1
pubmed:volume
70
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
9538-43
pubmed:meshHeading
pubmed:year
2010
pubmed:articleTitle
Integration of host-related signatures with cancer cell-derived predictors for the optimal management of anticancer chemotherapy.
pubmed:affiliation
INSERM, U1015, Institut Gustave Roussy, Villejuif, France.
pubmed:publicationType
Journal Article, Review, Research Support, Non-U.S. Gov't